查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1630453

照护现场资料管理软体 -市场占有率分析、产业趋势与统计、成长预测（2025-2030 年）

Point-of-Care Data Management Software - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
出版日期: | 出版商: Mordor Intelligence | 英文 100 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预测期内，照护现场资料管理软体市场预计将以 12.3% 的复合年增长率成长

护理点资料管理软体-市场-IMG1

主要亮点

  • 由于医疗保健领域价值观的变化和技术的发展，对就地检验的需求正在增加。有几个因素推动了 POCT 的需求。其中包括感染疾病的增加、心臟疾病和糖尿病等与文明病的增加、想要使用家用 POC 设备的患者的增加以及使设备更快、更容易使用的技术进步。
  • 全球估计有 5.11 亿成年人患有糖尿病。到 2040 年，这一数字预计将增加到 5.7 亿以上。随着糖尿病在世界各地持续增加，还需要努力提高人们的意识。预计 37% 的成人糖尿病患者居住在亚太地区。另外，根据国际糖尿病联盟的数据，2021年全球糖尿病患者人数为5.37亿人。 2021 年至 2045 年间，全球糖尿病照护支出预计将从 9.66 亿美元成长到 10.53 亿美元。根据美国疾病管制与预防中心 (CDC) 最近的一份报告，超过 50% 的被诊断患有 COVID-19 的糖尿病患者正在住院治疗。
  • 透过就地检验(POCT) 快速诊断临床症状可以改善患者的治疗结果。 POCT 发展背后的关键理念是，它可以透过使测试更接近患者并快速轻鬆地向医疗保健专业人员提供结果来加快诊断和治疗速度。现今的 POCT 设备正在发生变化，但取得记录合规性所需的资料仍然非常耗时。强大的 POCT 管理系统和连接解决方案可减少手动输入结果所需的时间，消除手动输入中固有的错误，并促进即时存取结果，帮助医疗保健专业人员做出及时的决策。
  • 此外，随着医疗资料分析越来越普遍地用于支援以患者为中心的护理和人口健康管理，POCT 结果可以以电子方式集成，结果追踪指标和关键绩效指标也必须包含在内。 2015年至2019年，美国电子健康记录（EHR）支出将以5.4%的复合年增长率成长，2019年总计达到145亿美元。此外，根据日本护理协会的调查，2019年9月至10月，日本约63%的医院引进了EMR系统。该国政府自 2000 年代初以来一直在推广该系统的使用。
  • COVID-19 的爆发给世界各地的卫生系统带来了巨大的压力，这些系统难以应对大量需要挽救生命的治疗的患者。一些国家正在目睹或准备应对关键医疗设备的短缺，例如外科口罩、面罩、救生人工呼吸器或患者的实体空间和床位。在日益高科技的医疗设备世界中，这些看似基本的必需品被优先考虑。

照护现场(POC)资料管理软体市场趋势

医院/重症患者监护室细分市场预计将占据主要市场占有率

  • 医院越来越多地使用就地检验(POCT) 和电子健康记录系统，从而提高了即时电子结果报告的重要性。 POCT资料管理系统随着市场需求的变化而不断发展以支援此类模型。在各个医院中，从一个校园到另一个校园，或从一个州到另一个州，基于网路的互联资料管理平台极大地释放了就地检验专案管理的效率。
  • 照护现场(POC) 技术最重要的方面是其床边存在。 POC 技术促进并改善患者与护理师、医生和外科医生之间的互动，从而改善医疗保健结果。床边血糖检测是最广泛、容量最大的 POC 市场。这些是第一批开发的设备，涉及数百台设备和数千名操作员。
  • 此外，透过在每个房间/治疗区域安装壁挂式 POC 终端或轮式工作站，任何医院都可以节省大量缩短时间和成本。各种研究得出的结论是，护士花 25% 到 50% 的轮班时间来完成记录，而传统上是使用铅笔和纸来填写病历。这意味着护理人员经常参与准确搜寻、创建、修改和储存关键患者资料。
  • 此外，加护病房(ICU)/重症患者监护病房的临床医生经常在有限的空间内治疗重症患者，此时他们必须快速做出决定。因此，POCT 越来越多地被用作重症监护病房患者管理的常规组成部分，特别是血气分析。虽然血液气体分析仪 (BGA) 的主要目的是提供血液气体水平（例如 pH、pO2、pCO2）的精确测量，但现代分析仪目前不测量血红蛋白或电解质浓度（例如钠）。包括钾、氯和离子钙。
  • 西班牙一家医院与 NTT 资料(NTT DATAzGroup) 合作开发了 SmartICU，让医生和技术人员与 NTT 资料的资料科学家组成团队，以取得更好的临床结果。在与医院合作开发 SmartICU 解决方案的为期一年的旅程开始时，团队发现资料管理和彙报是一个关键障碍。
  • 鑑于护理师每小时手动测量的非结构化性质，关键病房资料来源远远超出了高级仪器测量的范围。团队花了一些时间来发现、整合、设计和客製化资料仪表板。在此基础上，医院和 NTT 资料团队专注于最具附加价值的分析场景。

预计北美将占据较大市场占有率

  • 数十年来，北美地区一直使用就地检验(POCT) 来诊断和监测急性和慢性疾病。用于诊断爱滋病毒、结核病和疟疾等感染疾病的快速检测正在变得可用，这主要是由于医生和患者能够透过智慧型手机可视化结果并做出适当的临床决策。变化。照护现场诊断市场也受到诊断行业最新创新的推动，这些创新为支持治疗方法的快速临床决策提供快速诊断。
  • 根据美国疾病管制与预防中心的数据，慢性呼吸道疾病，包括慢性阻塞性肺病和气喘，是美国第四大死因。每年有超过 16 万人死亡。在美国，五分之一的慢性阻塞性肺病患者预计将在 30 天内再次入院。
  • POC 招聘受到政府的青睐。 POC 检测减轻了医院资源的负担，减少了急诊室的等待时间和就诊次数。生产中的大多数 POC 测试都是为检测感染疾病而设计的。例如，美国国家生物医学影像和生物工程研究所建立的Point of Care技术研究网络正在加速POC诊断和检测产品的开发。有利的法规，例如临床实验室改进法案 (CLIA) 指南，比其他形式更促进 POC 测试。
  • 目前，美国的POC检测包括化学/电解质、怀孕、血红蛋白、心臟生物标记、血液学、粪便潜血、滥用药物、肝功能、血气和有限的感染疾病。由于现有的心臟生物标记POC 测试存在缺陷，MEDITECH 的Expanse Point of Care 软体为护理师和治疗师提供了一种基于网路的现代化解决方案，以便与患者互动并提供最佳、最高效的护理。 感染疾病's Daughters 引入了行动技术。根据地理位置和潜在的感染疾病，可以针对流行病、复杂的紧急情况或灾难量身定制 POC 资源。
  • 随着医疗界迫切需要准确及时的虚拟策略来改善患者照护，特别是在感染疾病爆发的情况下，Evoke360 不仅可以提高护理品质和患者治疗效果，还可以影响品质和风险调整评分，提高利润率以及供应商组织的竞争日益激烈。 2020 年 6 月， 资料 Software (DataLink) 指出了 Evoke360 及其提供者关係管理 (PRM) 模组的主要优势，可协助提供者从按服务付费转向基于价值的护理。 Evoke360 充当照护现场(POC) 解决方案，聚合来自不同来源的资料，以加速对患者的先发製人护理，并缩小护理差距，超越诊断和治疗。

照护现场(POC)资料管理软体产业概述

由于多家公司参与，照护现场(POC)资料管理软体市场竞争非常激烈。市场似乎适度分散，主要企业采取产品创新、併购和收购等策略来扩大市场渗透率并保持竞争力。该市场的主要企业包括西门子 Healthineers AG、雅培 Point of Care Inc. 和丹纳赫公司 (Danaher Corporation)。

  • 2022 年 1 月，Glytec 与罗氏在胰岛素管理领域展开合作。这项数位健康合作关係将罗氏的医疗设备和 IT 解决方案专业知识与 Glytec 经 FDA 批准的胰岛素剂量决策支援软体 Glucommander 相结合，以解决医院床边住院患者血糖管理的挑战，旨在透过实现即时资料照护现场。
  • 2022 年 2 月，Butterfly Network, Inc.（一家透过手持式全身超音波改变医疗保健的数位健康公司）和 Ambra Health（一家 Intelerad 公司和领先的云端基础的医疗影像管理套件的製造商）宣布，他们将共享床边服务互通性。此次合作增强了 Butterfly Blueprint 企业平台的可扩展性，改善了医院和卫生系统之间有价值的超音波资讯的存取和共用。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 3 个月分析师支持

目录

第一章简介

  • 研究假设和市场定义
  • 调查范围

第二章调查方法

第三章执行摘要

第四章市场动态

  • 市场概况
  • 市场驱动因素
    • 灵活连接和软体介面解决方案的创新
    • 增加医疗基础设施预算
    • 政府努力普及POC测试
  • 市场问题
    • 高实施成本和营运挑战
  • 市场机会
    • 快速侦测并分散医疗服务
  • 波特五力分析
    • 供应商的议价能力
    • 买方议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争公司之间的敌对关係
  • 当前监管状态（临床实验室改进法案 CLIA 指南和连接标准 (POCT1-A2)）
  • 就地检验的新应用（败血症生物标记、内分泌测试、中风标记等）

第五章 COVID-19 对市场的影响

第六章 市场细分

  • 按最终用户
    • 医院/重症患者加护病房
    • 诊断中心
    • 诊所/门诊病人
  • 按用途
    • 感染疾病装置
    • 血糖监测
    • 凝血监测
    • 尿液检查
    • 心臟代谢监测
    • 癌症标记物
    • 血液学
    • 其他 POC 应用
  • 按地区
    • 北美洲
      • 美国
      • 加拿大
    • 欧洲
      • 德国
      • 英国
      • 义大利
      • 法国
      • 欧洲其他地区
    • 亚太地区
      • 印度
      • 日本
      • 中国
      • 新加坡
      • 其他亚太地区
    • 拉丁美洲
    • 中东/非洲

第七章 竞争格局

  • 公司简介
    • Siemens Healthineers AG+（Conworx）
    • Abbott Point of Care Inc.+（Alere）
    • Danaher Company（HemoCue and Radiometer Medical ApS）
    • Roche Diagnostics Corporation
    • TELCOR Inc.
    • Orchard Software Corporation
    • Randox Laboratories Ltd
    • Thermo Fisher Scientific Inc.

第八章投资分析

第9章市场的未来

简介目录
Product Code: 71564

The Point-of-Care Data Management Software Market is expected to register a CAGR of 12.3% during the forecast period.

Point-of-Care Data Management Software - Market - IMG1

Key Highlights

  • The demand for point-of-care testing is growing in response to the value shift in healthcare and technological developments. Several factors are driving the need for POCT. Some of them include an increase in infectious diseases, a rise in lifestyle-related diseases, such as cardiac diseases and diabetes, a growing patient desire to use home-based POC devices, and technological advancements creating faster and easier-to-use devices.
  • Around the globe, an estimated 511 million adults have diabetes. By 2040, this number is expected to rise to over 5,70 million. As diabetes worldwide continues to increase, so must the effort to raise awareness. 37% of all diabetic adults are expected to live in the Asia-Pacific region. Additionally, according to the International Diabetes Federation, the number of diabetic patients worldwide in 2021 was 537 million. Between 2021 - 2045, the global expenditures for diabetes treatment are anticipated to grow from USD 966 million to USD 1,053 million. According to a recent report by the Centers for Disease Control and Prevention (CDC), more than 50% of people with diabetes who have been diagnosed with COVID-19 are hospitalized.
  • Rapid diagnosis of clinical conditions through point-of-care testing (POCT) can improve patient outcomes. The primary concept behind POCT growth is that bringing testing closer to the patient and results quickly and conveniently to the provider can speed up the diagnosis and treatment. Today's POCT devices are changing, but capturing the data required to document compliance is still time-consuming. A robust POCT management system and connectivity solution reduces the time spent manually typing in results, eliminates errors inherent to manually entered results, and facilitates real-time access to results so that providers can make timely decisions.
  • Additionally, as healthcare data analytics are more commonly used to support patient-centered care and population health management, it is essential to have POCT results electronically integrated to include results tracking metrics and key performance indicators. Electronic medical records (EHR) expenditures in the United States grew at an annual average of 5.4% from 2015 to 2019, totaling USD 14.5 billion in 2019. Additionally, according to the Japanese Nursing Association survey, from September to October 2019, around 63% of the hospitals in Japan implemented the system of EMR. The government in the country has been promoting the system's use since the beginning of the 2000s.
  • The COVID-19 outbreak placed a significant burden on healthcare systems worldwide that are straining to handle the volume of ill patients requiring life-saving treatment. Several countries have witnessed or are preparing for shortages of critical medical equipment such as surgical masks, face shields, life-saving ventilators, or even the physical space and beds for patients. These seemingly fundamental necessities become the priority in a world of increasingly high-tech healthcare equipment.

Point-of-Care (POC) Data Management Software Market Trends

Hospitals/Critical Care Units Segment is Expected to Hold a Significant market Share

  • The point-of-care testing (POCT) and electronic medical records system usage are rising in hospitals, where the importance of real-time electronic reporting of results is increasing. POCT data management systems are evolving to meet the marketplace's changing needs in supporting such a model. Across the hospitals, either from campus to campus or from one state/province to another, the web-based connectivity data management platform unlocks primary efficiency in point-of-care testing program management.
  • The most critical aspect of POC (point-of-care) technology is its presence at the bedside. POC technologies facilitate and improve interactions between patients and their nurses, doctors, and surgeons, leading to better healthcare outcomes. Bedside glucose testing is the most widespread and occupies the most massive volume in the POC market. These were the first devices developed and involved hundreds of devices and thousands of operators.
  • Further, a wall-mounted POC terminal in every room/treatment area or workstation on wheels has the potential to create significant time and cost savings in any hospital. Various studies concluded that nurses spend 25-50% of their shifts on documentation done in the traditional manner, which is on a physical chart with a pencil and paper. This means that nurses are regularly involved in accurate retrieval, production, modification, and critical patient data storage.
  • Further, clinicians in intensive care units (ICU)/critical care units often work with critically ill patients in limited space and must make quick decisions at that point of care. Thus, critical care units have increasingly used POCT as a routine element of patient management, notably for blood gas analysis. The primary objective of the blood gas analyzer (BGA) is to deliver accurate measures of the blood gas levels (such as pH, pO2, and pCO2); however, modern analyzers can currently measure additional parameters in the same blood sample, such as the hemoglobin or electrolyte concentrations (includes sodium, potassium, chloride, and ionized calcium).
  • The development of SmartICU at a hospital in Spain, in partnership with NTT DATA (an NTT DATAzGroup), is teaming its doctors and technologists with NTT DATA's data scientists to get better clinical results. At the outset of a one-year journey of developing the SmartICU solution with the hospital, the team identified data management and reporting as the primary obstacle.
  • Data sources at the critical units go far beyond high-level device readings when one considers them unstructured, such as the nurse's hourly measurements manually. The teams spent a certain amount of time on data discovery, integration, reporting dashboard designing, and customizing. With this foundation, the hospital and NTT DATA teams have focused on the most value-adding analytic scenarios to layer on top.

North America is Expected to Hold a Significant Market Share

  • Point-of-care testing (POCT) has been used in the North American region for several decades to diagnose and monitor acute and chronic medical conditions. The growing availability of rapid tests for diagnosing infectious diseases, such as HIV, TB, or malaria, that primarily enable physicians and patients to visualize the results from a smartphone and make appropriate clinical decisions may transform the market over the next few years. The point-of-care diagnostics market is also driven by the latest innovations in the diagnostics industry to provide an expedited diagnosis for quick clinical decision-making to support treatment regimens.
  • According to the Centers for Disease Control and Prevention, chronic lower respiratory diseases, including COPD and asthma, are the fourth-leading causes of mortality in the United States. They are responsible for more than 160,000 deaths a year. It is expected that 1 in 5 COPD patients will be readmitted within 30 days in the United States.
  • There is a preference for POC adoption by governments. POC testing reduces the strain on hospital resources, as well as ER wait times and visits. The majority of POC tests produced are designed for detecting infectious diseases. For instance, the Point of Care Technologies Research Network established by the United States National Institute of Biomedical Imaging and Bioengineering accelerates POC diagnostics or testing product development. Favorable regulations, such as the Clinical Laboratory Improvement Amendments (CLIA) guidelines, promote POC testing over other forms.
  • Presently, US POC testing caches comprise chemistry/electrolytes, pregnancy, hemoglobin, cardiac biomarkers, hematology, fecal occult blood, drugs of abuse, liver function, blood gases, and limited infectious diseases. Owing to the deficiencies with existing POC tests for cardiac biomarkers, MEDITECH's Expanse Point of Care software, the company's latest web-based mobile technology for nurses and therapists to provide the best and most efficient patient-facing care, has been implemented at King's Daughters Medical Center, aiming to eliminate infectious diseases. Depending on geographic location and potential infectious diseases, POC resources can be customized for pandemics, complex emergencies, or disasters.
  • As the healthcare community scrambles for accurate, timely, and virtual strategies to improve patient care, especially amid the COVID -19 pandemic, Evoke360 not only enhances the quality of care and patient outcomes but also impacts quality and risk adjustment scores that increase profit margins and give provider organizations a competitive edge. In June 2020, DataLink Software (DataLink) pointed to the key advantages of Evoke360 and its Provider Relations Management (PRM) module, enabling providers to transition from fee-for-service to value-based care. Evoke360 serves as a point-of-care solution, aggregating data from disparate sources to accelerate preemptive patient care, closing gaps in care to treat more than the diagnosis results.

Point-of-Care (POC) Data Management Software Industry Overview

The Point-of-Care Data Management Software Market is highly competitive, owing to the presence of multiple players in the market. The market appears to be moderately fragmented, with the key players adopting strategies such as product innovation, mergers, and acquisitions, to expand their reach and stay competitive in the market. Some of the market's major players are Siemens Healthineers AG, Abbott Point of Care Inc., and Danaher Corporation, among others.

  • In January 2022, Glytec and Roche struck a partnership on insulin management. This digital health collaboration combines Roche's expertise in medical devices and IT solutions with Glytec's FDA-cleared insulin dosing decision support software, Glucommander, to address the challenges with inpatient blood sugar management at the hospital bedside, designed to improve patient safety and care by empowering point-of-care clinicians to collect and take immediate action on glycaemic management data.
  • In February 2022, Butterfly Network, Inc., a digital health company transforming care with handheld, whole-body ultrasound, and Ambra Health, an Intelerad Company and maker of a leading cloud-based medical image management suite, announced a partnership to accelerate and simplify interoperability for bedside imaging data. This partnership strengthens Butterfly Blueprint's enterprise platform's scalability and will enhance access and shareability of valuable ultrasound information across hospitals and health systems.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Innovation in Flexible Connectivity and Software Interface Solutions
    • 4.2.2 Rise in Healthcare Infrastructure Budgets
    • 4.2.3 Government Initiatives for Promoting the Deployment of POC Testing
  • 4.3 Market Challenges
    • 4.3.1 High Deployment Costs and Operational Challenges
  • 4.4 Market Opportunities
    • 4.4.1 Rapid Testing and Decentralized Healthcare
  • 4.5 Porters Five Force Analysis
    • 4.5.1 Bargaining Power of Suppliers
    • 4.5.2 Bargaining Power of Buyers
    • 4.5.3 Threat of New Entrants
    • 4.5.4 Threat of Substitutes
    • 4.5.5 Intensity of Competitive Rivalry
  • 4.6 Current Regulatory Landscape (Guidelines of Clinical Laboratory Improvement Amendments CLIA) and Connectivity Standards (POCT1-A2))
  • 4.7 Emerging Applications in Point-of-Care Testing (Sepsis Biomarkers, Endocrine Testing, Stroke Markers, etc.)

5 IMPACT OF COVID-19 ON THE MARKET

6 MARKET SEGMENTATION

  • 6.1 By End User
    • 6.1.1 Hospitals/Critical Care Units
    • 6.1.2 Diagnostic Centers
    • 6.1.3 Clinics/Outpatient
  • 6.2 By Application
    • 6.2.1 Infectious Disease Devices
    • 6.2.2 Glucose Monitoring
    • 6.2.3 Coagulation Monitoring
    • 6.2.4 Urinalysis
    • 6.2.5 Cardiometabolic Monitoring
    • 6.2.6 Cancer Markers
    • 6.2.7 Hematology
    • 6.2.8 Other POC Applications
  • 6.3 By Geography
    • 6.3.1 North America
      • 6.3.1.1 United States
      • 6.3.1.2 Canada
    • 6.3.2 Europe
      • 6.3.2.1 Germany
      • 6.3.2.2 United Kingdom
      • 6.3.2.3 Italy
      • 6.3.2.4 France
      • 6.3.2.5 Rest of Europe
    • 6.3.3 Asia-Pacific
      • 6.3.3.1 India
      • 6.3.3.2 Japan
      • 6.3.3.3 China
      • 6.3.3.4 Singapore
      • 6.3.3.5 Rest of Asia-Pacific
    • 6.3.4 Latin America
    • 6.3.5 Middle East & Africa

7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Siemens Healthineers AG + (Conworx)
    • 7.1.2 Abbott Point of Care Inc. + (Alere)
    • 7.1.3 Danaher Company (HemoCue and Radiometer Medical ApS)
    • 7.1.4 Roche Diagnostics Corporation
    • 7.1.5 TELCOR Inc.
    • 7.1.6 Orchard Software Corporation
    • 7.1.7 Randox Laboratories Ltd
    • 7.1.8 Thermo Fisher Scientific Inc.

8 INVESTMENT ANALYSIS

9 FUTURE OF THE MARKET